Myeloid derived suppressor cells are reduced and T regulatory cells stabilised in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega 3

Pancreatic adenocarcinoma (PAC) is a devastating condition, with the majority of patients presenting with metastatic or locally advanced disease. In these patients their disease is classified as advanced pancreatic cancer (APC), which is incurable and associated with survivals generally of a few mon...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of translational medicine 2020-03, Vol.8 (5), p.172-172
Hauptverfasser: Isherwood, John, Arshad, Ali, Chung, Wen Yuan, Runau, Franscois, Cooke, Jill, Pollard, Cristina, Howells, Lynne, Fishwick, Jenny, Thompson, John, Metcalfe, Matthew, Steward, William, Dennison, Ashley
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 172
container_issue 5
container_start_page 172
container_title Annals of translational medicine
container_volume 8
creator Isherwood, John
Arshad, Ali
Chung, Wen Yuan
Runau, Franscois
Cooke, Jill
Pollard, Cristina
Howells, Lynne
Fishwick, Jenny
Thompson, John
Metcalfe, Matthew
Steward, William
Dennison, Ashley
description Pancreatic adenocarcinoma (PAC) is a devastating condition, with the majority of patients presenting with metastatic or locally advanced disease. In these patients their disease is classified as advanced pancreatic cancer (APC), which is incurable and associated with survivals generally of a few months. The overall survival (OS) for pancreatic cancer has not changed significantly in the past forty years with multiple trials demonstrating disappointing results. Immune modulatory cells particularly myeloid derived suppressor cells (MDSCs) and T regulatory cells (Tregs) are important mediators in PAC. Omega 3 fatty acids (ω-3FAs) have been shown to have anti-inflammatory properties and there is now evidence demonstrating the benefit of ω-3FAs in PAC. This was a single-center cohort study investigating intravenous ω-3FAs and gemcitabine chemotherapy versus gemcitabine therapy only in patients with APC. Here, we investigated levels of MDSCs and Tregs and examined how these changes correlated with survival. Eighteen trial and nine control patients were recruited. There was a significant benefit in progression-free survival (PFS) in trial compared to control patients (P=0.0003). Median survival in trial patients was 5.65 months compared to 1.8 months in control patients. There was no significant benefit in OS in trial compared to control patients (P=0.13). Median survival in trial patients was 7 months compared to 2.9 months in control patients. MDSCs were significantly decreased in trial patients (P=0.0001) but not control patients. Conversely Tregs were significantly increased in control patients (P=0.005) but not in trial patients. Administration of ω-3FAs with gemcitabine chemotherapy in APC results in a significant decrease of MDSCs and stability of Tregs. This may be secondary to the reduction of pro-inflammatory mediators. A phase three randomized trial is justified to further examine these effects.
doi_str_mv 10.21037/atm.2020.02.02
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7154395</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2392461007</sourcerecordid><originalsourceid>FETCH-LOGICAL-c323t-5c9463ffff4d47b29309e002124a711d9eddc1c0fc31d689c5845dafb1f85fc3</originalsourceid><addsrcrecordid>eNpVUU1v2zAMNYoVa9H2vNug4y5JKcmOo8uAodhHgQ675C4oEp2qsCVPkjPkN-1Pjk6zohUISOR7fCTFqvrAYSk4yPbWlGEpQMASBNlZdSkkNItmLdW7V--L6ibnJwDggisJ8L66kAQqydVl9ffnAfvoHXOY_B4dy9M4Jsw5Jmax7zMzCVlCN1kCTXBsQ95u6k2J6XCi5GK2vveZGD6w0RSPoWT2x5dHZtzehDl3pCshYZbZOZJYmV1CjrwdDtbPOgGPZXwoyewxxCmzOODOMHldnXemz3hzuq-qzbevm7sfi4df3-_vvjwsLM1VFo1V9Up2dGpXt1tBMysEEFzUpuXcKXTOcgudldyt1so267pxptvybt1Q8Kr6_Cw7TtsBncW5k16PyQ8mHXQ0Xr9Fgn_Uu7jXLW9qqRoS-HQSSPH3hLnowef5p0xAGkcLqUS94gAtUW-fqTbFnBN2L2U46OOSNS1Zz0vWIMgo4-Pr7l74_1cq_wGv7qio</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2392461007</pqid></control><display><type>article</type><title>Myeloid derived suppressor cells are reduced and T regulatory cells stabilised in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega 3</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Isherwood, John ; Arshad, Ali ; Chung, Wen Yuan ; Runau, Franscois ; Cooke, Jill ; Pollard, Cristina ; Howells, Lynne ; Fishwick, Jenny ; Thompson, John ; Metcalfe, Matthew ; Steward, William ; Dennison, Ashley</creator><creatorcontrib>Isherwood, John ; Arshad, Ali ; Chung, Wen Yuan ; Runau, Franscois ; Cooke, Jill ; Pollard, Cristina ; Howells, Lynne ; Fishwick, Jenny ; Thompson, John ; Metcalfe, Matthew ; Steward, William ; Dennison, Ashley</creatorcontrib><description>Pancreatic adenocarcinoma (PAC) is a devastating condition, with the majority of patients presenting with metastatic or locally advanced disease. In these patients their disease is classified as advanced pancreatic cancer (APC), which is incurable and associated with survivals generally of a few months. The overall survival (OS) for pancreatic cancer has not changed significantly in the past forty years with multiple trials demonstrating disappointing results. Immune modulatory cells particularly myeloid derived suppressor cells (MDSCs) and T regulatory cells (Tregs) are important mediators in PAC. Omega 3 fatty acids (ω-3FAs) have been shown to have anti-inflammatory properties and there is now evidence demonstrating the benefit of ω-3FAs in PAC. This was a single-center cohort study investigating intravenous ω-3FAs and gemcitabine chemotherapy versus gemcitabine therapy only in patients with APC. Here, we investigated levels of MDSCs and Tregs and examined how these changes correlated with survival. Eighteen trial and nine control patients were recruited. There was a significant benefit in progression-free survival (PFS) in trial compared to control patients (P=0.0003). Median survival in trial patients was 5.65 months compared to 1.8 months in control patients. There was no significant benefit in OS in trial compared to control patients (P=0.13). Median survival in trial patients was 7 months compared to 2.9 months in control patients. MDSCs were significantly decreased in trial patients (P=0.0001) but not control patients. Conversely Tregs were significantly increased in control patients (P=0.005) but not in trial patients. Administration of ω-3FAs with gemcitabine chemotherapy in APC results in a significant decrease of MDSCs and stability of Tregs. This may be secondary to the reduction of pro-inflammatory mediators. A phase three randomized trial is justified to further examine these effects.</description><identifier>ISSN: 2305-5839</identifier><identifier>EISSN: 2305-5839</identifier><identifier>DOI: 10.21037/atm.2020.02.02</identifier><identifier>PMID: 32309319</identifier><language>eng</language><publisher>China: AME Publishing Company</publisher><subject>Original</subject><ispartof>Annals of translational medicine, 2020-03, Vol.8 (5), p.172-172</ispartof><rights>2020 Annals of Translational Medicine. All rights reserved.</rights><rights>2020 Annals of Translational Medicine. All rights reserved. 2020 Annals of Translational Medicine.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c323t-5c9463ffff4d47b29309e002124a711d9eddc1c0fc31d689c5845dafb1f85fc3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154395/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154395/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32309319$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Isherwood, John</creatorcontrib><creatorcontrib>Arshad, Ali</creatorcontrib><creatorcontrib>Chung, Wen Yuan</creatorcontrib><creatorcontrib>Runau, Franscois</creatorcontrib><creatorcontrib>Cooke, Jill</creatorcontrib><creatorcontrib>Pollard, Cristina</creatorcontrib><creatorcontrib>Howells, Lynne</creatorcontrib><creatorcontrib>Fishwick, Jenny</creatorcontrib><creatorcontrib>Thompson, John</creatorcontrib><creatorcontrib>Metcalfe, Matthew</creatorcontrib><creatorcontrib>Steward, William</creatorcontrib><creatorcontrib>Dennison, Ashley</creatorcontrib><title>Myeloid derived suppressor cells are reduced and T regulatory cells stabilised in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega 3</title><title>Annals of translational medicine</title><addtitle>Ann Transl Med</addtitle><description>Pancreatic adenocarcinoma (PAC) is a devastating condition, with the majority of patients presenting with metastatic or locally advanced disease. In these patients their disease is classified as advanced pancreatic cancer (APC), which is incurable and associated with survivals generally of a few months. The overall survival (OS) for pancreatic cancer has not changed significantly in the past forty years with multiple trials demonstrating disappointing results. Immune modulatory cells particularly myeloid derived suppressor cells (MDSCs) and T regulatory cells (Tregs) are important mediators in PAC. Omega 3 fatty acids (ω-3FAs) have been shown to have anti-inflammatory properties and there is now evidence demonstrating the benefit of ω-3FAs in PAC. This was a single-center cohort study investigating intravenous ω-3FAs and gemcitabine chemotherapy versus gemcitabine therapy only in patients with APC. Here, we investigated levels of MDSCs and Tregs and examined how these changes correlated with survival. Eighteen trial and nine control patients were recruited. There was a significant benefit in progression-free survival (PFS) in trial compared to control patients (P=0.0003). Median survival in trial patients was 5.65 months compared to 1.8 months in control patients. There was no significant benefit in OS in trial compared to control patients (P=0.13). Median survival in trial patients was 7 months compared to 2.9 months in control patients. MDSCs were significantly decreased in trial patients (P=0.0001) but not control patients. Conversely Tregs were significantly increased in control patients (P=0.005) but not in trial patients. Administration of ω-3FAs with gemcitabine chemotherapy in APC results in a significant decrease of MDSCs and stability of Tregs. This may be secondary to the reduction of pro-inflammatory mediators. A phase three randomized trial is justified to further examine these effects.</description><subject>Original</subject><issn>2305-5839</issn><issn>2305-5839</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpVUU1v2zAMNYoVa9H2vNug4y5JKcmOo8uAodhHgQ675C4oEp2qsCVPkjPkN-1Pjk6zohUISOR7fCTFqvrAYSk4yPbWlGEpQMASBNlZdSkkNItmLdW7V--L6ibnJwDggisJ8L66kAQqydVl9ffnAfvoHXOY_B4dy9M4Jsw5Jmax7zMzCVlCN1kCTXBsQ95u6k2J6XCi5GK2vveZGD6w0RSPoWT2x5dHZtzehDl3pCshYZbZOZJYmV1CjrwdDtbPOgGPZXwoyewxxCmzOODOMHldnXemz3hzuq-qzbevm7sfi4df3-_vvjwsLM1VFo1V9Up2dGpXt1tBMysEEFzUpuXcKXTOcgudldyt1so267pxptvybt1Q8Kr6_Cw7TtsBncW5k16PyQ8mHXQ0Xr9Fgn_Uu7jXLW9qqRoS-HQSSPH3hLnowef5p0xAGkcLqUS94gAtUW-fqTbFnBN2L2U46OOSNS1Zz0vWIMgo4-Pr7l74_1cq_wGv7qio</recordid><startdate>202003</startdate><enddate>202003</enddate><creator>Isherwood, John</creator><creator>Arshad, Ali</creator><creator>Chung, Wen Yuan</creator><creator>Runau, Franscois</creator><creator>Cooke, Jill</creator><creator>Pollard, Cristina</creator><creator>Howells, Lynne</creator><creator>Fishwick, Jenny</creator><creator>Thompson, John</creator><creator>Metcalfe, Matthew</creator><creator>Steward, William</creator><creator>Dennison, Ashley</creator><general>AME Publishing Company</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>202003</creationdate><title>Myeloid derived suppressor cells are reduced and T regulatory cells stabilised in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega 3</title><author>Isherwood, John ; Arshad, Ali ; Chung, Wen Yuan ; Runau, Franscois ; Cooke, Jill ; Pollard, Cristina ; Howells, Lynne ; Fishwick, Jenny ; Thompson, John ; Metcalfe, Matthew ; Steward, William ; Dennison, Ashley</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c323t-5c9463ffff4d47b29309e002124a711d9eddc1c0fc31d689c5845dafb1f85fc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Original</topic><toplevel>online_resources</toplevel><creatorcontrib>Isherwood, John</creatorcontrib><creatorcontrib>Arshad, Ali</creatorcontrib><creatorcontrib>Chung, Wen Yuan</creatorcontrib><creatorcontrib>Runau, Franscois</creatorcontrib><creatorcontrib>Cooke, Jill</creatorcontrib><creatorcontrib>Pollard, Cristina</creatorcontrib><creatorcontrib>Howells, Lynne</creatorcontrib><creatorcontrib>Fishwick, Jenny</creatorcontrib><creatorcontrib>Thompson, John</creatorcontrib><creatorcontrib>Metcalfe, Matthew</creatorcontrib><creatorcontrib>Steward, William</creatorcontrib><creatorcontrib>Dennison, Ashley</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of translational medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Isherwood, John</au><au>Arshad, Ali</au><au>Chung, Wen Yuan</au><au>Runau, Franscois</au><au>Cooke, Jill</au><au>Pollard, Cristina</au><au>Howells, Lynne</au><au>Fishwick, Jenny</au><au>Thompson, John</au><au>Metcalfe, Matthew</au><au>Steward, William</au><au>Dennison, Ashley</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Myeloid derived suppressor cells are reduced and T regulatory cells stabilised in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega 3</atitle><jtitle>Annals of translational medicine</jtitle><addtitle>Ann Transl Med</addtitle><date>2020-03</date><risdate>2020</risdate><volume>8</volume><issue>5</issue><spage>172</spage><epage>172</epage><pages>172-172</pages><issn>2305-5839</issn><eissn>2305-5839</eissn><abstract>Pancreatic adenocarcinoma (PAC) is a devastating condition, with the majority of patients presenting with metastatic or locally advanced disease. In these patients their disease is classified as advanced pancreatic cancer (APC), which is incurable and associated with survivals generally of a few months. The overall survival (OS) for pancreatic cancer has not changed significantly in the past forty years with multiple trials demonstrating disappointing results. Immune modulatory cells particularly myeloid derived suppressor cells (MDSCs) and T regulatory cells (Tregs) are important mediators in PAC. Omega 3 fatty acids (ω-3FAs) have been shown to have anti-inflammatory properties and there is now evidence demonstrating the benefit of ω-3FAs in PAC. This was a single-center cohort study investigating intravenous ω-3FAs and gemcitabine chemotherapy versus gemcitabine therapy only in patients with APC. Here, we investigated levels of MDSCs and Tregs and examined how these changes correlated with survival. Eighteen trial and nine control patients were recruited. There was a significant benefit in progression-free survival (PFS) in trial compared to control patients (P=0.0003). Median survival in trial patients was 5.65 months compared to 1.8 months in control patients. There was no significant benefit in OS in trial compared to control patients (P=0.13). Median survival in trial patients was 7 months compared to 2.9 months in control patients. MDSCs were significantly decreased in trial patients (P=0.0001) but not control patients. Conversely Tregs were significantly increased in control patients (P=0.005) but not in trial patients. Administration of ω-3FAs with gemcitabine chemotherapy in APC results in a significant decrease of MDSCs and stability of Tregs. This may be secondary to the reduction of pro-inflammatory mediators. A phase three randomized trial is justified to further examine these effects.</abstract><cop>China</cop><pub>AME Publishing Company</pub><pmid>32309319</pmid><doi>10.21037/atm.2020.02.02</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2305-5839
ispartof Annals of translational medicine, 2020-03, Vol.8 (5), p.172-172
issn 2305-5839
2305-5839
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7154395
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central
subjects Original
title Myeloid derived suppressor cells are reduced and T regulatory cells stabilised in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega 3
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T18%3A45%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Myeloid%20derived%20suppressor%20cells%20are%20reduced%20and%20T%20regulatory%20cells%20stabilised%20in%20patients%20with%20advanced%20pancreatic%20cancer%20treated%20with%20gemcitabine%20and%20intravenous%20omega%203&rft.jtitle=Annals%20of%20translational%20medicine&rft.au=Isherwood,%20John&rft.date=2020-03&rft.volume=8&rft.issue=5&rft.spage=172&rft.epage=172&rft.pages=172-172&rft.issn=2305-5839&rft.eissn=2305-5839&rft_id=info:doi/10.21037/atm.2020.02.02&rft_dat=%3Cproquest_pubme%3E2392461007%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2392461007&rft_id=info:pmid/32309319&rfr_iscdi=true